Marinomed Biotech AG (MARI)
Vienna Exchange · Austria · prices in EUR · close of 15 Oct 2026
Key indicators
| Last close | EUR 4.000 |
|---|---|
| 52-week range | 2.200 – 21.000 |
| Return, 1 month / 3 months | −11.1% / −55.3% |
| Return, 1 year / 3 years | −79.9% / −90.0% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 105.9% |
| Worst drawdown (1 year) | -81.9% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Marinomed Biotech AG is an Austrian biopharmaceutical company based in Korneuburg. It develops and licenses products built on its own technology platforms, including a polymer derived from red algae used in nasal sprays and lozenges that address cold and allergy symptoms, and a solubilising technology that improves the delivery of poorly soluble drugs. The company works with commercial partners to bring its consumer health products to pharmacies and markets in several countries, while also pursuing prescription applications of its platforms.
On this site Marinomed Biotech AG appears as a stock on the Vienna Exchange (Austria), code MARI, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Marinomed Biotech AG (MARI) trades on the Vienna Exchange in Austria. It last closed at EUR 4.000 on 15 October 2026.
Its price-based Market X-Ray is 5 out of 100 (a weak price profile), ranking 84 of 84 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 79.9% and over the last three months it fell 55.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Vienna Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 1 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -63.2% | ||
| From 52-week high | -81.0% | ||
| Momentum | 2 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -55.3% | ||
| 6-month return | -71.0% | ||
| 12-month return, skipping the last month | -77.4% | ||
| Stability (higher is calmer) | 2 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 105.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -81.9% | ||
| Liquidity | 22 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 35.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −11.1% |
| 3 months | −55.3% |
| 6 months | −71.0% |
| 1 year | −79.9% |
| 3 years | −90.0% |
| 5 years | −96.3% |
Signals
| 50-day / 200-day average | 4.366 / 10.867 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.044 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Vienna Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.